Jacquelyn W. Chou, MPP, MPL

home / authors / jacquelyn-w-chou-mpp-mpl

Articles

December 5th 2023

Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C

Jacquelyn W. Chou, MPP, MPL Marlon Graf, PhD Oliver Díaz Espinosa, PhD Iris Brewer, MS Zachary Heim, BS James Baumgardner, PhD

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

November 13th 2018

Understanding and Improving Value Frameworks With Real-World Patient Outcomes

Anupam B. Jena, MD, PhD Jacquelyn W. Chou, MPP, MPL Lara Yoon, MPH Wade M. Aubry, MD Jan Berger, MD, MJ Wayne Burton, MD A. Mark Fendrick, MD Donna M. Fick, RN, PhD David Franklin, BA Rebecca Killion, MA Darius N. Lakdawalla, PhD Peter J. Neumann, ScD Kavita Patel, MD, MSHS John Yee, MD, MPH Brian Sakurada, PharmD Kristina Yu-Isenberg, PhD, MPH, RPh

New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.

June 15th 2016

Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events

Anupam B. Jena, MD, PhD Daniel M. Blumenthal, MD, MBA Warren Stevens, PhD Jacquelyn W. Chou, MPP, MPL Thanh G.N. Ton, PhD Dana P. Goldman, PhD

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.